CobimetinibSelective MEK inhibitor CAS# 934660-93-2 |
2D Structure
- U0126-EtOH
Catalog No.:BCC1066
CAS No.:1173097-76-1
- PD98059
Catalog No.:BCC1098
CAS No.:167869-21-8
- PD184352 (CI-1040)
Catalog No.:BCC1112
CAS No.:212631-79-3
- SL-327
Catalog No.:BCC1123
CAS No.:305350-87-2
- MEK162 (ARRY-162, ARRY-438162)
Catalog No.:BCC1148
CAS No.:606143-89-9
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 934660-93-2 | SDF | Download SDF |
PubChem ID | 16222096 | Appearance | Powder |
Formula | C21H21F3IN3O2 | M.Wt | 531.31 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | GDC-0973; XL518 | ||
Solubility | DMSO : ≥ 100 mg/mL (188.21 mM) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]-[3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin-1-yl]methanone | ||
SMILES | C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O | ||
Standard InChIKey | BSMCAPRUBJMWDF-KRWDZBQOSA-N | ||
Standard InChI | InChI=1S/C21H21F3IN3O2/c22-14-6-5-13(19(18(14)24)27-16-7-4-12(25)9-15(16)23)20(29)28-10-21(30,11-28)17-3-1-2-8-26-17/h4-7,9,17,26-27,30H,1-3,8,10-11H2/t17-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Cobimetinib is a novel selective MEK inhibitor, and the IC50 value against MEK1 is 4.2 nM.In Vitro:The EC50 values of Cobimetinib (GDC-0973) for 888MEL and A2058 cells are 0.2 μM, 10 μM, respectivelly. Melanoma cells are treated with EC50 concentration of MEK and PI3K inhibitors for 24 hours (888MEL: 0.05 μM GDC-0973, 2.5 μM GDC-0941; A2058: 2.5 μM GDC-0973, 2.5 μM GDC-0941)[1]. Mitochondrial OXPHOS limits cell death induced by cobimetinib (100 nM) in melanoma with constitutive MAPK activation in A375 cells[4].In Vivo:In the NCI-H2122 KRASG12C mutant non-small cell lung carcinoma (NSCLC) xenograft model, treatment with up to 5 mg/kg Cobimetinib (GDC-0973) lead to moderate TGI and at 10 mg/kg approaches tumor stasis[1]. GDC-0973 and GDC-0941 are administered to A2058 tumor-bearing mice daily (QD) or every third day (Q3D) either as single agents or in combination. The population rate constants associated with tumor growth inhibition for GDC-0973 and GDC-0941 are 0.00102 and 0000651 μM-1 h-1, respectively[2]. Following single doses of GDC-0973 (1, 3, or 10 mg/kg, p.o.) estimated in vivo IC50 values of %pERK decrease based on tumor concentrations in xenograft mice are 0.78 (WM-266-4) and 0.52 μM (A375)[3]. References: |
Cobimetinib Dilution Calculator
Cobimetinib Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.8821 mL | 9.4107 mL | 18.8214 mL | 37.6428 mL | 47.0535 mL |
5 mM | 0.3764 mL | 1.8821 mL | 3.7643 mL | 7.5286 mL | 9.4107 mL |
10 mM | 0.1882 mL | 0.9411 mL | 1.8821 mL | 3.7643 mL | 4.7054 mL |
50 mM | 0.0376 mL | 0.1882 mL | 0.3764 mL | 0.7529 mL | 0.9411 mL |
100 mM | 0.0188 mL | 0.0941 mL | 0.1882 mL | 0.3764 mL | 0.4705 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Cobimetinib is a selective inhibitor of mitogen-activated protein kinase kinase (MEK) with IC50 value of 0.9 nM [1].
MEK is a kinase enzyme which selectively phosphorylates Ser/Thr and Tyr residues and involved in the mitogen-activated protein kinase (MAPK) signaling pathways that play an important role in regulation of cell proliferation, survival, differentiation, motility and angiogenesis [2].
In a KRAS G13D and B-RAF G464V mutant MDA-MB-231T breast adenocarcinoma cells, Cobimetinib inhibited MEK with IC50 value of 0.2 nM [1]. In pharmacokinetic-pharmacodynamic (PK-PD) model, Cobimetinib showed a sustained tumor pharmacodynamic response due to longer residence in tumor than in plasma [3].
In WM-266-4 xenograft mice, Cobimetinib decreased %pERK in tumor with IC50 values of 0.78 (WM-266-4) and 0.52 mM. Also, Cobimetinib (3.89 mM) increased IC50 value in WM-266-4 mice. In A375 xenograft mice, Cobimetinib (0.3-30 mg/kg) showed antitumor efficacy in a dose-dependent way. Cobimetinib is currently in phase I clinical trials as a potential antitumor agent [3].
References:
[1]. Rice KD, Aay N, Anand NK, et al. Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973). ACS Med Chem Lett, 2012, 3(5): 416-421.
[2]. Akinleye A, Furqan M, Mukhi N, et al. MEK and the inhibitors: from bench to bedside. J Hematol Oncol, 2013, 6: 27.
[3]. Wong H, Vernillet L, Peterson A, et al. Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor. Clin Cancer Res, 2012, 18(11): 3090-3099.
- 8-Deacetylyunaconitine
Catalog No.:BCN7609
CAS No.:93460-55-0
- TAK-901
Catalog No.:BCC2180
CAS No.:934541-31-8
- Glucoliquiritin
Catalog No.:BCN6760
CAS No.:93446-18-5
- Conantokin G
Catalog No.:BCC6120
CAS No.:93438-65-4
- ENMD-2076
Catalog No.:BCC2186
CAS No.:934353-76-1
- HSP990 (NVP-HSP990)
Catalog No.:BCC5491
CAS No.:934343-74-5
- GSK1014802(CNV1014802)
Catalog No.:BCC6454
CAS No.:934240-30-9
- A-966492
Catalog No.:BCC2211
CAS No.:934162-61-5
- Venlafaxine
Catalog No.:BCC9190
CAS No.:93413-69-5
- Desvenlafaxine
Catalog No.:BCC5038
CAS No.:93413-62-8
- Chamaechromone
Catalog No.:BCN3718
CAS No.:93413-00-4
- 2-Benzothiazolol
Catalog No.:BCC8557
CAS No.:934-34-9
- Cobimetinib (R-enantiomer)
Catalog No.:BCC1493
CAS No.:934660-94-3
- Cobimetinib (racemate)
Catalog No.:BCC1492
CAS No.:934662-91-6
- Karavilagenin D
Catalog No.:BCN4480
CAS No.:934739-29-4
- Glimepiride
Catalog No.:BCC2109
CAS No.:93479-97-1
- 2-Iodomelatonin
Catalog No.:BCC6772
CAS No.:93515-00-5
- (4->2)-Abeo-16-hydroxycleroda-2,13-dien-15,16-olide-3-al
Catalog No.:BCN7498
CAS No.:935293-70-2
- TH-237A
Catalog No.:BCC5378
CAS No.:935467-97-3
- Euphorbia factor L7a
Catalog No.:BCN3784
CAS No.:93550-94-8
- MDL 72527
Catalog No.:BCC6060
CAS No.:93565-01-6
- AZD1480
Catalog No.:BCC2191
CAS No.:935666-88-9
- BIX 01294
Catalog No.:BCC1131
CAS No.:935693-62-2
- AR-42 (OSU-HDAC42)
Catalog No.:BCC2161
CAS No.:935881-37-1
Cobimetinib: inhibiting MEK1/2 in BRAF V600-mutant melanoma.[Pubmed:28112278]
Drugs Today (Barc). 2016 Nov;52(11):593-605.
Historically, metastatic melanoma has had extremely poor survival outcomes. The outlook, however, is rapidly changing as new molecularly targeted therapies have vastly improved patient outcomes. One such therapy is the potent mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor Cobimetinib. Recently, Cobimetinib was approved for the treatment of metastatic or unresectable melanoma with serine/threonine-protein kinase B-raf (BRAF) V600E or V600K mutations when used in combination with the BRAF inhibitor vemurafenib. Currently, multiple clinical trials are investigating this drug combination for the treatment of various cancer types (e.g., breast, melanoma, colorectal). In the phase III coBRIM trial, this combination therapy showed improved melanoma response rates and patient progression-free survival when compared to vemurafenib alone. Additionally, toxicities were generally found to be manageable with dose modification or interruption. However, tumor response to BRAF/MEK inhibition, though rapid, is often short-lived as tumors develop resistance to this combination therapy. Therefore, new trials are beginning to investigate the addition of a third targeted agent or immunotherapy in order to increase the durability of treatment response. These trials are already showing promising preliminary results.
Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients.[Pubmed:28052762]
J Hematol Oncol. 2017 Jan 4;10(1):3.
BACKGROUND: Metastatic melanoma is an aggressive form of skin cancer with a high mortality rate and the fastest growing global incidence rate of all malignancies. The introduction of BRAF/MEK inhibitor combinations has yielded significant increases in PFS and OS for melanoma. However, at present, no direct comparisons between different BRAF/MEK combinations have been conducted. In light of this, an indirect treatment comparison was performed between two BRAF/MEK inhibitor combination therapies for metastatic melanoma, dabrafenib plus trametinib and vemurafenib plus Cobimetinib, in order to understand the relative efficacy and toxicity profiles of these therapies. METHODS: A systematic literature search identified two randomized trials as suitable for indirect comparison: the coBRIM trial of vemurafenib plus Cobimetinib versus vemurafenib and the COMBI-v trial of dabrafenib plus trametinib versus vemurafenib. The comparison followed the method of Bucher et al. and analyzed both efficacy (overall survival [OS], progression-free survival [PFS], and overall response rate [ORR]) and safety outcomes (adverse events [AEs]). RESULTS: The indirect comparison revealed similar efficacy outcomes between both therapies, with no statistically significant difference between therapies for OS (hazard ratio [HR] 0.94, 95% confidence interval [CI] 0.68 - 1.30), PFS (HR 1.05, 95% CI 0.79 - 1.40), or ORR (risk ratio [RR] 0.90, 95% CI 0.74 - 1.10). Dabrafenib plus trametinib differed significantly from vemurafenib plus Cobimetinib with regard to the incidence of treatment-related AE (RR 0.92, 95% CI 0.87 - 0.97), any AE grade >/=3 (RR 0.71, 95% CI 0.60 - 0.85) or dose interruption/modification (RR 0.77, 95% CI 0.60 - 0.99). Several categories of AEs occurred significantly more frequently with vemurafenib plus Cobimetinib, while some occurred significantly more frequently with dabrafenib plus trametinib. For severe AEs (grade 3 or above), four occurred significantly more frequently with vemurafenib plus Cobimetinib and no severe AE occurred significantly more frequently with dabrafenib plus trametinib. CONCLUSIONS: This indirect treatment comparison suggested that dabrafenib plus trametinib had comparable efficacy to vemurafenib plus Cobimetinib but was associated with reduced adverse events.